Last reviewed · How we verify
2B3-101
At a glance
| Generic name | 2B3-101 |
|---|---|
| Also known as | Glutathione pegylated liposomal doxorubicin hydrochloride, glutathione pegylated liposomal doxorubicin |
| Sponsor | BBB-Therapeutics B.V. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Safety of a New Micellar Glutathione Formulation (NA)
- Biological Evaluation of Dietary Supplement Liposomal Glutathione (NA)
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. (PHASE1, PHASE2)
- Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2B3-101 CI brief — competitive landscape report
- 2B3-101 updates RSS · CI watch RSS
- BBB-Therapeutics B.V. portfolio CI